About
Kardigan, Inc.
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases.
The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure.
It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking.
Kardigan, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:KARD
Valuation & Multiples
Key valuation ratios and metrics
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-06-29 | $24.00 | $27.00 | $23.60 | $25.90 | $25.90 | +1.90 | 1,376,100 |
| 2026-06-26 | $22.27 | $24.54 | $21.88 | $23.60 | $23.60 | +1.33 | 852,400 |
| 2026-06-25 | $22.28 | $23.88 | $21.19 | $22.58 | $22.58 | +0.30 | 298,900 |
| 2026-06-24 | $21.68 | $23.21 | $21.26 | $22.03 | $22.03 | +0.35 | 472,300 |
| 2026-06-23 | $22.96 | $24.86 | $21.50 | $22.24 | $22.24 | -0.72 | 548,400 |
| 2026-06-22 | $21.29 | $24.00 | $20.07 | $22.77 | $22.77 | +1.48 | 922,100 |
| 2026-06-18 | $16.25 | $23.75 | $16.25 | $22.00 | $22.00 | +5.75 | 5,844,400 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13G | Jun 29, 2026 | Filing |
| SCHEDULE 13D | Jun 29, 2026 | Filing |
| SCHEDULE 13D | Jun 25, 2026 | Filing |
| 8-K | Jun 23, 2026 | Current Report |
| 424B4 | Jun 18, 2026 | Prospectus |
| EFFECT | Jun 17, 2026 | Notice of Effectiveness |
| S-1MEF | Jun 17, 2026 | Registration adding securities to prior Form S-1 registration |
| S-8 | Jun 17, 2026 | Securities to be offered to employees in employee benefit plans |
| CERT | Jun 17, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Jun 15, 2026 | Registration of securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Tassos Gianakakos
Chief Executive Officer, Director, and Chair
Brianne Puglisi
Chief Financial Officer
Jay Edelberg
Chief Medical Officer
Andy Pasternak
Chief Strategy Officer
John B. Moriarty, Jr.
Chief Legal Officer and Corporate Secretary
Paul Berns
Director
Douglas Giordano
Director
David Meeker, M.D.
Director
Kim Popovits
Director
Tim Walbert
Director
